The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of cancer.

Co-developed by Amgen and Allergan, Mvasi is the first anti-cancer biosimilar to be approved by the FDA and is largely similar to Avastin (bevacizumab).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mvasi can be used in combination with chemotherapy for non-squamous non-small-cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), glioblastoma, metastatic renal cell carcinoma in combination with interferon alfa, and for persistent, recurrent, or metastatic carcinoma of the cervix.

Amgen research and development executive vice-president Dr Sean E. Harper said: “The approval of Mvasi marks a significant milestone for healthcare practitioners and patients as the first anti-cancer biosimilar approved in the US.

“With decades of experience in oncology and biologics, Amgen continues to expand its biosimilar and oncology portfolios, and Mvasi has the potential to advance access to high-quality, targeted cancer therapy.”

"The approval of Mvasi marks a significant milestone for healthcare practitioners and patients as the first anti-cancer biosimilar approved in the US."

Mvasi is a biosimilar to bevacizumab, a recombinant immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to vascular endothelial growth factor (VEGF) and inhibits the interaction of VEGF with its receptors, VEGF receptor-1 and VEGF receptor-2.

This inhibits establishment of new blood vessels that are essential for the maintenance and growth of solid tumours.

The current FDA approval is based on a comprehensive data package that revealed the similarity of Mvasi with bevacizumab, with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products.

Also, the clinical studies included data from a Phase III trial conducted on patients with NSCLC.